title: Oral erythromycin accelerates impaired gastrointestinal motility after endoscopic mucosal resection.
abstract: Gastrointestinal motility may be impaired after endoscopic mucosal resection of gastric lesions. We investigated whether oral erythromycin could improve motility. Twenty patients were divided randomly into groups that received oral omeprazole with or without erythromycin. Motility was recorded overnight at 3 days before and 4 days after endoscopic resection using a microtransducer probe. In the group without erythromycin, gastric phase III activity decreased significantly after endoscopic resection, while it was increased significantly by erythromycin (P < 0.01). After resection, there were significantly more gastric phase III events in the erythromycin group (P < 0.05). The interval between the start of the evening meal and the initial gastric phase III activity was significantly prolonged after resection, while this interval was significantly shortened by erythromycin (P < 0.05). The gastric phase III cycle length was also significantly shortened by erythromycin (P < 0.05). Postprandial and fasting gastrointestinal motility were impaired after endoscopic resection, and postprandial as well as fasting motility were improved by oral erythromycin.
authors.affiliation: Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Gunma, Maebashi, Japan. osamuk@med.gunma-u.ac.jp
authors.forename: Osamu
authors.initials: O
authors.lastname: Kawamura
authors.forename: Motoyasu
authors.initials: M
authors.lastname: Kusano
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Shimoyama
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Horikoshi
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Sekiguchi
authors.forename: Masatomo
authors.initials: M
authors.lastname: Mori
mesh_terms: D000236:Adenoma / Q000503:physiopathology / Q000601:surgery; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D016099:Endoscopy, Gastrointestinal / Q000379:methods*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D004917:Erythromycin / Q000008:administration & dosage*; D005215:Fasting / Q000502:physiology; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000601:surgery*; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage; D011184:Postoperative Period; D013270:Stomach / Q000187:drug effects / Q000503:physiopathology* / Q000601:surgery; D013274:Stomach Neoplasms / Q000503:physiopathology / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D005765:Gastrointestinal Agents; D004917:Erythromycin; D009853:Omeprazole